Table of contents
What if a single shipment could change the course of a patient's life? As the cell and gene therapy (C>) market grows, the need for precision and reliability in healthcare logistics becomes even more crucial.
Key Topics:
- Investment in cell and gene therapy to support growing market demands.
- Advancing patient outcomes through direct-to-patient and direct-from-patient models.
- Managing complex supply chains with a focus on patient privacy and safety.
- Advanced digital tools for tracking temperature and location of high-value shipments.
Michael Sweeney, Global Head of Strategy at QuickSTAT, shares insights on how his organization is investing in infrastructure, technology, and partnerships to support these life-changing therapies. Discover how digital tools are revolutionizing the way sensitive shipments are tracked and how patient privacy is safeguarded. Watch Part 1 now and be sure to watch Part 2 for additional insights.
Video Highlights:
- 00:50 - Could you share some background on QuickSTAT and your current role?
- 02:22 - What strategic investments is QuickSTAT prioritizing?
- 06:40 - How is technology advancing to better support direct-to-patient?
- 09:35 - How does QuickSTAT protect the privacy of patients?
- 11:28 - What is QuickSTAT’s strategy for investing in supply chain digitalization, considering varying regional regulatory requirements?
- 14:33 - What are the challenges associated with managing a complex supply chain for high-value and highly-sensitive biological shipments?
- 17:10 - What are the unique workflows and dataflows for cell and gene therapies?
